 Genprex Inc NASDAQ:GNPX said its collaborators have presented positive preclinical data for the combination of REQORSA, the companys proprietary TUSC2 immunogene therapy, in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer NSCLC. These data were presented in two presentations at the 2021 American Association of Cancer Research AACR annual meeting, the company said. 